CN119156395A - 用于递送治疗剂的环肽 - Google Patents

用于递送治疗剂的环肽 Download PDF

Info

Publication number
CN119156395A
CN119156395A CN202380034351.1A CN202380034351A CN119156395A CN 119156395 A CN119156395 A CN 119156395A CN 202380034351 A CN202380034351 A CN 202380034351A CN 119156395 A CN119156395 A CN 119156395A
Authority
CN
China
Prior art keywords
side chain
amino acid
formula
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034351.1A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·多尔蒂
凯尔·A·托塔罗
阿曼达·东布罗斯基
赖利·吉斯勒
周明
马修·斯特里特
亚历克·戈菲
钱自清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ant Rada Therapeutics Ltd By Share Ltd
Original Assignee
Ant Rada Therapeutics Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ant Rada Therapeutics Ltd By Share Ltd filed Critical Ant Rada Therapeutics Ltd By Share Ltd
Publication of CN119156395A publication Critical patent/CN119156395A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380034351.1A 2022-04-22 2023-04-21 用于递送治疗剂的环肽 Pending CN119156395A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263363450P 2022-04-22 2022-04-22
US63/363,450 2022-04-22
US202263354471P 2022-06-22 2022-06-22
US63/354,471 2022-06-22
US202263377754P 2022-09-30 2022-09-30
US63/377,754 2022-09-30
PCT/US2023/019452 WO2023205451A1 (en) 2022-04-22 2023-04-21 Cyclic peptides for delivering therapeutics

Publications (1)

Publication Number Publication Date
CN119156395A true CN119156395A (zh) 2024-12-17

Family

ID=86332269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034351.1A Pending CN119156395A (zh) 2022-04-22 2023-04-21 用于递送治疗剂的环肽

Country Status (6)

Country Link
US (1) US20250289851A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511385A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513521A (cg-RX-API-DMAC7.html)
CN (1) CN119156395A (cg-RX-API-DMAC7.html)
CA (1) CA3249036A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023205451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518476A (ja) * 2021-05-10 2024-05-01 エントラーダ セラピューティクス,インコーポレイティド mRNAスプライシングを調節するための組成物及び方法
WO2025038901A1 (en) 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
CN121772940A (zh) 2023-08-17 2026-03-31 恩特拉达治疗学股份有限公司 寡核苷酸的细胞内靶向
WO2026136957A2 (en) 2024-12-20 2026-06-25 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US20030087861A1 (en) 2001-05-17 2003-05-08 Iversen Patrick L Combined approach to treatment of cancer using a c-myc antisense oligomer
US6828105B2 (en) 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2005072527A2 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US7402574B2 (en) 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006287530A1 (en) 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
LT2735568T (lt) 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
CA2691673A1 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
EP3133160B1 (en) 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
CN103154009B (zh) 2010-09-30 2015-06-10 日本新药株式会社 吗啉基核酸衍生物
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
ES2727481T3 (es) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
JP6477464B2 (ja) 2013-05-24 2019-03-06 味の素株式会社 モルフォリノオリゴヌクレオチドの製造方法
PT3149025T (pt) * 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
TW202500573A (zh) * 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
TWI812647B (zh) 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
WO2019165183A1 (en) * 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US12012427B2 (en) 2019-10-31 2024-06-18 Indian Association For The Cultivation Of Science Synthesis of Fmoc-protected morpholino monomers and their use in the synthesis of morpholino oligomer
JP2023553360A (ja) 2020-12-11 2023-12-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 ポリ-モルホリノオリゴヌクレオチドギャップマー
IL308353A (en) * 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
US20250228953A1 (en) * 2021-11-08 2025-07-17 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides

Also Published As

Publication number Publication date
CA3249036A1 (en) 2023-10-26
JP2025513521A (ja) 2025-04-24
US20250289851A1 (en) 2025-09-18
WO2023205451A1 (en) 2023-10-26
EP4511385A1 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
US20250289851A1 (en) Cyclic peptides for delivering therapeutics
US10300109B2 (en) Peptidomimetic macrocycles
EP0986539A1 (en) Dna-binding pyrrole and imidazole polyamide derivatives
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
US20230312653A1 (en) Cyclic cell penetrating peptides
WO2012173846A2 (en) Peptidomimetic macrocycles
US6506906B1 (en) Preparation and use of bifunctional molecules having DNA sequence binding specificity
CZ20022740A3 (cs) Sloučenina, způsob přípravy sloučeniny, farmaceutický prostředek a způsob léčení rakoviny
US20250090675A1 (en) Polypeptide conjugates for intracellular delivery of nucleic acids
CN111447941A (zh) 用于细胞内递送装订肽的多肽缀合物
Dastpeyman et al. Modular synthesis of trifunctional peptide-oligonucleotide conjugates via native chemical ligation
JP2008504235A (ja) 細胞分裂阻害剤として7位にて環状ペプチドと接合したカンプトテシン
CN121772940A (zh) 寡核苷酸的细胞内靶向
Yang Applications of Benzotriazol-1-yloxy compounds in peptide synthesis
TW202426031A (zh) EphA2結合待定肽及包含其之組成物
Christensen et al. Pyrazines on Solid Support from Peptides by Periodinane Oxidation of Threonine Side‐Chains. A Quantitative Chemical Transformation (QCT) for Combinatorial Chemistry
AU747300B2 (en) DNA binding pyrrole and imidazole polyamide derivatives
US10385096B2 (en) Pro-Amb reverse turn restricted bioactive peptide analogues
US20030207400A1 (en) Vectors for dna delivery
JPH09278669A (ja) 腎炎治療薬
JP2002514209A (ja) 副溝における、キラルヘアピンポリアミドのdna結合親和性、配列特異性、および配向優先性の立体化学的制御

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination